Infections and Association With Different Intensity of Chemotherapy in Children With Acute Myeloid Leukemia

被引:86
作者
Sung, Lillian [1 ]
Gamis, Alan [2 ]
Alonzo, Todd A. [3 ,4 ]
Buxton, Allen [4 ]
Britton, Kristen [5 ]
DeSwarte-Wallace, Joetta [6 ]
Woods, William G. [7 ]
机构
[1] Hosp Sick Children, Div Hematol Oncol, Dept Pediat, Toronto, ON M5G 1X8, Canada
[2] Childrens Mercy Hosp, Dept Hematol Oncol, Kansas City, MO 64108 USA
[3] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA
[4] Childrens Oncol Grp, Arcadia, CA USA
[5] Sinai Hosp, Dept Pediat Hematol Oncol, Baltimore, MD 21215 USA
[6] Harbor UCLA Med Ctr, Miller Childrens Hosp, Dept Hematol Oncol, Long Beach, CA USA
[7] Emory Univ, Childrens Healthcare Atlanta, Aflac Canc Ctr, Atlanta, GA 30322 USA
关键词
infections; children; acute myeloid leukemia; stem cell transplantation; COLONY-STIMULATING FACTOR; CANCER; MORTALITY; INDUCTION; METAANALYSIS; PROPHYLAXIS; REMISSION; THERAPY; DEATHS; TRIALS;
D O I
10.1002/cncr.24107
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: The objectives were to compare infections during different intensities of therapy in children with acute myeloid leukemia (AML). METHODS: Subjects were children enrolled in Children's Cancer Group 2891 with AML. In phase 1 (induction), patients were randomized to intensive or standard timing. In phase 2 (consolidation), those with a family donor were allocated allogeneic stem cell transplantation (SCT); the remainder were randomized to autologous SCT or chemotherapy. This report compares infections between different treatments on an intent-to-treat basis. RESULTS: During phase 1, intensive timing was associated with more bacterial (57.7% vs 39.4%; P < .001), fungal (27.4% vs 9.9%; P < .001), and viral (14.0% vs 3.9%; P < .001) infections compared with standard timing. During phase 2, chemotherapy was associated with more bacterial (56.5% vs 40.1%; P = .005), but similar fungal (9.5% vs 6.1%; P = 1.000) and viral (4.2% vs 12.9%; P = .728) infections compared with allogeneic SCT. No differences between chemotherapy and autologous SCT infections were seen. Fatal infections were more common during intensive compared with standard timing induction (5.5% vs 0.9%; P = .004). Infectious deaths were similar between chemotherapy, autologous SCT, and allogeneic SCT. CONCLUSIONS: Prevalence of infection varies depending on the intensity and type of treatment. This information sheds insight into the mechanisms behind susceptibility and outcome of infections in pediatric AML. Cancer 2009;115:1100-8. (c) 2009 American Cancer Society.
引用
收藏
页码:1100 / 1108
页数:9
相关论文
共 14 条
[1]   Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: A report from the children's cancer group [J].
Alonzo, TA ;
Kobrinsky, NL ;
Aledo, A ;
Lange, BJ ;
Buxton, AB ;
Woods, WG .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2002, 24 (08) :627-635
[2]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[3]   Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98 [J].
Creutzig, U ;
Zimmermann, M ;
Reinhardt, D ;
Dworzak, M ;
Stary, J ;
Lehrnbecher, T .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) :4384-4393
[4]   Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation [J].
Dekker, Allison ;
Bulley, Sean ;
Beyene, Joseph ;
Dupuis, L. Lee ;
Doyle, John J. ;
Sung, Lillian .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (33) :5207-5215
[5]   Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis [J].
Engels, EA ;
Lau, J ;
Barza, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) :1179-1187
[6]   Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients [J].
Gafter-Gvili, A ;
Fraser, A ;
Paul, M ;
Leibovici, L .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (12) :979-995
[7]   Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: A report from the Children's Cancer Group study CCG-2891 [J].
Gamis, AS ;
Howells, WB ;
DeSwarte-Wallace, J ;
Feusner, JH ;
Buckley, JD ;
Woods, WG .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (09) :1845-1855
[8]   Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group [J].
Lange, Beverly J. ;
Smith, Franklin O. ;
Feusner, James ;
Barnard, Dorothy R. ;
Dinndorf, Patricia ;
Feig, Stephen ;
Heerema, Nyla A. ;
Arndt, Carola ;
Arceci, Robert J. ;
Seibel, Nita ;
Weiman, Margie ;
Dusenbery, Kathryn ;
Shannon, Kevin ;
Luna-Fineman, Sandra ;
Gerbing, Robert B. ;
Alonzo, Todd A. .
BLOOD, 2008, 111 (03) :1044-1053
[9]   Mortality in overweight and children with acute myeloid underweight leukemia [J].
Lange, BJ ;
Gerbing, RB ;
Feusner, J ;
Skolnik, J ;
Sacks, N ;
Smith, FO ;
Alonzo, TA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (02) :203-211
[10]   Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93 [J].
Lehrnbecher, T ;
Varwig, D ;
Kaiser, J ;
Reinhardt, D ;
Klingebiel, T ;
Creutzig, U .
LEUKEMIA, 2004, 18 (01) :72-77